TCE

Technology

Last mentioned: Mar 20, 2026

Timeline

  1. Profitability Target

    Antengene aims to achieve its first full year of profitability.

  2. Profitability Target

    Anticipated inflection point for company-wide net profitability.

  3. AACR 2026

    Antengene scheduled to present data on next-generation ADCs and TCEs.

  4. Earnings Release

    2025 full-year results announced, highlighting first TCE out-licensing.

  5. 2025 FY Results

    Company announces full-year results and confirms shift toward 2026 profitability.

  6. UCB Partnership

    Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.

  7. Fiscal Year End

    Antengene concludes its most significant R&D year to date.

Stories mentioning TCE 2

pharma Bullish

Antengene Eyes 2026 Profitability Following Landmark TCE Out-Licensing Deal

Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.

3 sources